Financials
Our markets
We are an international pharmaceutical company. Our headquarters are based in Italy, where we are deeply rooted as one of the leading companies in primary care.
Thanks to our 17 subsidiaries around the world and several top distributors, we distribute our products in more than 90 countries, with a global turnover in 2020 of approximately billion euro.
Half of this turnover is a result of our proprietary molecules, designed and developed in our R&D centers (Rifaximin, Sulodexide, Carnitine, L-methylfolate, Parnaparin).
Our second market is the US. After the acquisition of Pamlab in 2016, we now have a strong hold in the nutraceuticals and medical food sectors.
Spain, Romania, France and Poland are our other main markets as well as Russia and China.
Turnover
€ 1,05
billion in 2019
€ 521
million in Italy
€ 534,4
million RoW + Export & Licensing
molecules
Turnover
€ 989
millions in 2020
€ 481
millions in Italy
€ 508
millions RoW + Export & Licensing
Headcount

2900
Workforce

1700
Domestic

1200
International